The
Aurora kinases play a critical role in mitosis and have been suggested as promising targets for
cancer therapy due to their frequent overexpression in a variety of
tumors. Compared with established inhibitors of cell division such as the anti-tubulins, novel agents target mitotic
enzymes and show similar efficacy but with fewer side effects. Several small-molecule inhibitors of
Aurora kinases have been developed as
anticancer agents, some of which have progressed to early clinical evaluation. Here we identified
3-hydroxyflavone as a novel Aurora B inhibitor through high throughput screening.
3-Hydroxyflavone showed potent inhibition to Aurora B with the IC(50) on a nanomolar basis in the
enzyme-based
kinase activity assay. In the cell-based western blotting analysis,
3-hydroxyflavone dramatically decreased the phosphorylation level of
Histone H3 on the site of
serine 10, demonstrating the potent endogenous Aurora B activity inhibition in cell level. The followed cell image analysis provided the consist result. To make it clear whether
3-hydroxyflavone inhibited Aurora B by direct binding or not, SPR analysis was carried out to measure the affinity of interaction between Aurora B
protein and
3-hydroxyflavone and the result proved the binding with high affinity. Usually Aurora activity suppression induced
cancer cell proliferation inhibition. Colony formation and cell viability with/without treatment of
3-hydroxyflavone were measured using
CCK-8. The growth suppression under
3-hydroxyflavone present and the growth recovery after being released gave strong evidence that presence of
3-hydroxyflavone efficiently inhibited the fast growth of
cancer cells.